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proportion of droplets undergoing a phase change for a given 
set of ultrasound exposure conditions is also often very low. [ 12 ] 
Prior to conversion, nanodroplets cannot be continuously 
imaged under ultrasound and most current formulations rely 
on passive targeting, e.g., by the enhanced permeability and 
retention (EPR) effect. 
 In this study we examined potential solutions to these chal-
lenges. First, we investigated a hybrid protein–polymer shell for 
coating the nanodroplets consisting of human serum albumin 
(HSA) and poly(ethylene glycol) (PEG) ( Figure  1 ) with the aim 
of improving stability. Albumin coatings are widely used in par-
ticle formulations as they offer excellent biocompatibility and 
desirable surface properties. The binding affi nity for hydro-
phobic molecules is however limited and this limits the sta-
bility of albumin coated particles and hence their circulation 
time. Previous work [ 13 ] has indicated that cross-linking of the 
albumin using a polymer can generate extremely stable struc-
tures and our aim was to see whether this approach could be 
used to improve nanodroplet stability. Other studies have also 
shown that oleic acid-functionalized iron oxide nanocrystals 
(IONCs) can be very effectively stabilized with an aqueous dode-
cyltrimethylammonium bromide (DTAB) solution due to the 
hydrophobic van der Waals interaction between the oleic acid of 
IONCs and the hydrocarbon chains of DTAB. [ 14 ] We therefore 
also prepared nanodroplets containing PFC and IONCs coated 
with DTAB for comparison ( Table  1 ). 
 Second, we investigated the effect of loading the nano-
droplets with superparamagnetic solid nanoparticles to act 
as nucleation agents to promote phase transition thereby 
improving conversion effi ciency. The particles also potentially 
provide a means of manipulating the droplets using an external 
magnetic fi eld which has been shown in previous work to be 
highly advantageous for drug delivery. [ 10d ] We fi rst determined 
the effect upon the physical properties of the nanodroplets in 
terms of their size, surface charge, and stability under physi-
ological conditions. Their response to ultrasound exposure was 
then examined to determine conversion effi ciency, change in 
size and potential for image contrast enhancement. 
 Finally the ability of the nanodroplets to encapsulate, release, 
and promote uptake of a drug in a cancer cell line was tested. 
Albumin–PEG hybrid nanoparticles encapsulating super-
paramagnetic iron oxide and a hydrophobic drug (Paclitaxel) 
were prepared using an oil-in-water emulsifi cation method. 
These intermediate nanoparticles (mHSA) had an average dia-
meter of 232.0 ± 12.3 nm as measured by dynamic light scat-
tering (DLS). Following perfl uoropentane (PFP) loading, the 
 Ultrasound is one of the most widely applied clinical imaging 
modalities on account of its ability to provide real time images 
particularly of blood fl ow, its cost effectiveness, and high patient 
acceptability. [ 1–3 ] Over the past two decades, research into the 
therapeutic applications of ultrasound has also expanded 
signifi cantly for indications ranging from cancer therapy to 
thrombolysis. [ 4 ] An important area has been the development 
of gas-fi lled microbubbles both as image contrast agents and 
more recently as a means of enhancing therapeutic delivery. [ 5 ] 
Of particular interest is the fact that numerous studies have 
shown that microbubbles can facilitate the intracellular delivery 
of molecules under ultrasound exposure. [ 6 ] 
 Over the last decade there has been increasing interest in the 
use of liquid perfl uorocarbon (PFC) droplets as alternatives to 
microbubbles. [ 7 ] It has been shown that nanoscale droplets of 
appropriate size are able to pass through the endothelial gaps of 
defective blood vessels surrounding tumours, thus addressing 
the disadvantages of microbubbles, such as poor stability and 
micrometer size. [ 8,9 ] By selecting PFC liquids with the appro-
priate properties, nanodroplets can be fabricated so that they 
will undergo a phase transition upon exposure to ultrasound of 
suffi cient intensity and/or a temperature increase from another 
source. The resulting gas/vapour bubble can then be utilized for 
vascular imaging and/or therapeutic delivery either to promote 
drug uptake [ 2,10 ] or, e.g., for vessel occlusion, molecular recogni-
tion in cancer detection, or ablation for cancer therapy. [ 8,11 ] 
 Notwithstanding their signifi cant potential, the development 
of nanodroplets still poses some considerable challenges. While 
nanodroplet stability is greatly enhanced compared with that of 
microbubbles, it is still relatively poor compared with that of 
solid particles, [ 3 ] and droplets may undergo coalescence and/or 
premature phase transition before they reach the target region. 
Once in the target region, the conversion effi ciency, i.e., the 
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
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size of the nanodroplets (mHSA-PFP) was measured again 
and found to be 351.4 ± 18.5 nm and 416.2 ± 25.4 nm at 
20 °C and 37 °C, respectively. The latter measurement was 
made to determine whether there would be any change in vivo 
( Figure  2 a). 
 Earlier studies using the Antoine vapour pressure equa-
tion have shown that the estimated vaporization temperature 
of a PFP droplet should increase geometrically as the droplet 
size decreases into the sub-micrometer range. [ 15 ] Therefore 
nanodroplets containing liquid PFP should be stable at 
physiological temperatures, notwithstanding variations in 
surface tension produced by materials at the droplet sur-
face. [ 16 ] This was found to be true for the mHSA-PFP drop-
lets (Figure S1, Supporting Information) and should allow 
the particles to remain as droplets in the circulation rather 
than convert to microbubbles at 37 °C (i.e., following injec-
tion into the body) and subsequently to extravasate into 
tumours. The average size of the magnetic particle-loaded 
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 Figure 1.  a) Schematic representation of protein–polymer hybrid nanodroplets incorporating iron oxide nanocrystals, hydrophobic drugs, and per-
fl uoropentane. As the liquid PFP is vaporized upon ultrasound exposure, microscale bubbles are formed. This process also promotes the release of 
the encapsulated drugs through compromised areas of the protein–polymer coating. b) Different pathways of drug release and intracellular uptake: 
(1) after ultrasound exposure, drugs may be taken up by passive diffusion and sonoporation; (2) by endocytosis, droplets are degraded in the 
lysosomes, which facilitates drug release inside the cell.
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DTAB nanodroplets (mDTAB-PFP) however increased 
from 422 ± 24 nm at 20 °C to 1058 ± 53 nm at 37 °C. 
This may be attributed to aggregation of the droplets due to 
the relatively poor stabilization provided by the DTAB coating 
resulting in a lower vaporization temperature than would be 
predicted from the size distribution at 20 °C. 
 Transmission electron microscopy (TEM) was performed 
to confi rm the size and structure of both mHSA-PFP and 
mDTAB-PFP (Figure  2 b and Figure S1, Supporting Informa-
tion). It was not possible to directly observe the PFP liquid core 
under vacuum. However, the remaining hollow space inside 
the droplets was observed after gentle drying of the sample on 
the carbon grid. 
 Changes in the concentration of nanodroplets between 
200 and 800 nm were measured using the Nanosight system 
at 37 °C over a period of 10 d (Figure  2 c). The concentration 
of mDTAB-PFP decreased rapidly at 37 °C. Within 6 h, 49% 
of mDTAB-PFP were lost and only 7.2% remained after 10 d. 
However, the concentration of mHSA-PFP reduced by just 
3.5% in the fi rst 6 h, and 76% of nanodroplets were still detect-
able after 10 d. 
 Macroscopic observation of vials of droplets stored at 
37 °C also indicated that mHSA-PFP droplets were signifi cantly 
more stable than mDTAB-PFP (Figure S3, Supporting Informa-
tion). Similarly, in the case of the paclitaxel-loaded nanodrop-
lets, 82% of the initial concentration was detectable after 15 d 
and could still be readily vaporized upon ultrasound exposure 
(Figure S4, Supporting Information). These data indicate the 
stability of the HSA-PFP nanodroplets at in vivo temperatures, 
and, as shown in previous studies [ 7 ] this suggests that the cross 
linked albumin coating was able to increase the vaporization 
temperature of the PFP droplets signifi cantly above the bulk 
liquid boiling point of 29 °C (Figure S1, Supporting Infor-
mation). This stability may have been further augmented by 
disulfi de bonds between cysteine residues formed during soni-
cation. [ 17 ] Interestingly, the presence of magnetic nanoparticles 
also improved stability. This could perhaps be attributed to a 
form of Pickering stabilization, i.e., the solid hydrophobic par-
ticles accumulate at the interface of the perfl uorocarbon core 
(see Figure S2, Supporting Information) from which they are 
excluded on account of its combination of hydrophobicity and 
lipophobicity. The resulting surface layer then prevents both 
diffusion of the PFP or droplet coalescence. [ 18 ] 
 Using the experimental setup described in Figure S5 (Sup-
porting Information), nanodroplets were converted into micro-
bubbles under the action of continuous wave (CW) ultrasound. 
The experimentally measured resonant frequency and fi xed 
peak-to-peak voltage for the device were ≈1.85 MHz and 40 V, 
respectively. In addition, the resulting peak rarefactional 
pressure in the chamber was 265 kPa. Bright-fi eld optical 
microscopy images of mHSA-PFP, HSA-PFP, and mDTAB-
PFP suspended in pig plasma were captured before and after 
either 15 or 45 s of CW ultrasound exposure ( Figure  3 a). The 
highest concentration of microbubbles was generated by the 
mHSA-PFP droplets after 45 s. Equivalent ultrasound images 
are shown in Figure S6 in the Supporting Information. The 
changes in size distribution and concentration were quanti-
fi ed using the Nanosight system (Figure  3 b). The initial con-
centration of mHSA-PFP droplets was 6.2 × 10 8 particles mL −1 
before ultrasound exposure. After 15 s of continuous ultrasound 
exposure a dramatic decrease in the population of nanodroplets 
to 56% was observed, decreasing further to 29% after 45 s; i.e., 
≈70% of the droplets responded to ultrasound and underwent a 
phase change. The results for longer exposure times are shown 
in Figure S7 in the Supporting Information together with scan-
ning electron micrographs of droplets following ultrasound 
exposure (Figure S8, Supporting Information). 
 In contrast with the mHSA-PFP, the change in the HSA-PFP 
droplets was less dramatic; after 45 s 75% of the HSA-PFP drop-
lets were still present. This phenomenon could be explained 
by the magnetic nanoparticles acting as nucleation agents for 
the vaporization process. This hypothesis is supported by the 
results of previous studies in which solid particles were shown 
to reduce the vaporization threshold of nanodroplets (HSA-
PFP). [ 19 ] Other mechanisms may also be involved in lowering 
the droplet vaporization pressure threshold: e.g., changes in the 
acoustic properties of the droplets due to the IONCs could con-
tribute to superharmonic focusing effects which have also been 
shown to signifi cantly affect vaporization thresholds. [ 20 ] Inter-
estingly, phase transition was not so readily observed directly 
with mDTAB-PFP under the microscope; although the meas-
ured extent of the population decrease was 8% higher than that 
of HSA-PFP after 45 s. This may have been due to rapid disso-
lution of the resulting microbubbles. 
 The albumin–PEG conjugate coating appeared to provide 
stabilization for the microbubbles as well the nanodroplets. 
In Figure  3 c, the histogram of bubble sizes from mHSA-PFP 
nano droplets is shown, as determined by direct observation 
under the optical microscope. The average diameter of the con-
verted bubbles was 8.17 µm, and 64.1% of bubbles formed were 
smaller than 10 µm. However, the size of the observed micro-
bubbles formed by vaporization was twice as large as that pre-
dicted by theoretical approximation calculated using the ideal 
gas law ( PV =  nRT ). [ 21 ] When a droplet of PFP (molar mass: 
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 Table 1.  Formulations of nanodroplets and nanoparticles used in the experiments. 
Materials\nanodroplets HSA-PFP mHSA-PFP mpHSA-PFP mpHSA mDTAB-PFP
Core Magnetic particles (Fe 3 O 4 , 5 nm) 0 500 µg 500 µg 500 µg 500 µg
Paclitaxel (PTX) 0 0 500 µg 500 µg 0
Perfl uoropentane (PFP) 50 µL 50 µL 50 µL 0 50 µL
Shell Human serum albumin (HSA) 4 mg 4 mg 4 mg 4 mg 0
 bis -NHS-PEG 6 mg 6 mg 6 mg 6 mg 0
Dodecyltrimethyl-ammonium bromide (DTAB) 0 0 0 0 30 × 10 −3  M 
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0.288 kg mol −1 ) undergoes a phase conversion to the gaseous 
state at 37 ºC, it should expand to maximally 8.9 times its 
original diameter (neglecting surface tension effects and other 
deviations from the ideal gas law). This may have been due to 
coalescence of individual microbubbles in close proximity; or 
absorption of dissolved gases from the pig plasma which was 
not degassed. 
 Encapsulation of paclitaxel in the nanodroplets was meas-
ured by detecting UV absorbance of paclitaxel. The encap-
sulation effi ciency was 93% ± 6% and the maximum payload 
Adv. Mater. 2015, 27, 5484–5492
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 Figure 2.  a) Hydrodynamic diameters of mHSA-PFP (left) and mDTAB-PFP (right) at 20 °C and 37 °C. b) Transmission electron microscopy (TEM) 
images of mHSA-PFP and mDTAB-PFP droplets. c) Concentration changes of mHSA-PFP, HSA-PFP, and mDTAB-PFP over time at 37 °C. The initial 
concentrations of mHSA-PFP, HSA-PFP, and mDTAB-PFP nanodroplets were 4.7 × 10 9 , 4.6 × 10 9 , and 4.1 × 10 9 particles in mL, respectively.
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was about 0.096 mg mL −1 for paclitaxel-loaded mHSA-PFP 
nanodroplets (mpHSA-PFP). The in vitro release behavior of 
the mpHSA-PFP and paclitaxel-loaded mHSA nanoparticles 
(mpHSA, the maximum payload: 0.10 mg mL −1 ) was observed 
in the ultrasound fi eld (Figure  3 d). The release of paclitaxel 
from mpHSA-PFP was measured over the same time course, 
without ultrasound exposure. The concentration of released 
paclitaxel molecules was inferred from the degree of absorb-
ance intensity. Sustained release was found to be dependent 
upon the ultrasound exposure time. After 1 min of exposure, 
59% of the paclitaxel was released from the nanodroplets, and 
90% was released within 3 min. Conversely, less than 20% of 
the paclitaxel was released from mHSA nanoparticles in 3 min. 
The results indicate that the paclitaxel release of mHSA-PFP 
was in response to the ultrasound exposure. Furthermore, the 
release profi le is highly interrelated to the droplet-to bubble 
conversion rate. Unexposed nanodroplets released a negligible 
quantity of paclitaxel over the same time period. 
 The aim of magnetically guided drug delivery is to maxi-
mize the concentration of functionalized therapeutic agents at 
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 Figure 3.  a) Optical images of the mHSA-PFP, HSA-PFP, and mDTAB-PFP nanodroplets before and after 15 or 45 s of ultrasound exposure. Scale bars 
represent 200 µm. b) Normalized concentration of each nanodroplet before and after ultrasound exposure. The initial concentrations of mHSA-PFP, 
HSA-PFP, and mDTAB-PFP nanodroplets were 6.2 × 10 8 , 5.2 × 10 8 , and 4.9 × 10 8 particles per mL, respectively. c) Size distribution of bubbles produced 
from mHSA-PFP droplets by 1 min of ultrasound exposure. The initial concentration was 2.1 × 10 8 particles per mL. d) Release profi les of paclitaxel 
from mpHSA-PFP nanodroplets and mpHSA nanoparticles with varying ultrasound exposure time and mpHSA-PFP without ultrasound exposure. 
e) Localization, retention, and redispersion of mHSA-PFP nanodroplets in a vessel phantom under the infl uence of external magnetic fi eld. The short 
black  arrow in the 2nd panel indicates accumulated nanodroplets. The Initial concentration was 3.1 × 10 8 particles per mL, and mean blood velocity was 
11.6 cm s −1 .
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a target site using a magnetic fi eld. [ 22 ] Successful magnetic tar-
geting of the nanodroplets was observed in a vessel mimicking 
phantom in 95% pig blood, as shown in Figure  3 e. In this 
experiment, blood fl ow was fi xed at 11.6 cm s −1 which is in 
the range corresponding to venous fl ow. [ 23 ] In the absence of 
the magnet, the nanodroplets dispersed in the blood solution 
passed through the tube (Figure S9, Supporting Information). 
With the magnet, the mpHSA-PFP was rapidly concentrated at 
the wall of the tube closest to the magnet (fi eld = 0.4 T). After 
1 min, the magnet was removed and the accumulated droplets 
were carried away with no evidence of aggregation. Thus this 
method could be used to assist transport of nanodroplets to 
increase targeting effi ciency as compared with that achievable 
by, e.g., the EPR effect or biochemical targeting; although all 
three methods could be used in a complementary fashion. 
 The degree of cancer cell proliferation was determined to 
evaluate the therapeutic potential of the mpHSA-PFP droplets 
when they are exposed to ultrasound. Paclitaxel-free nano-
droplets (mHSA-PFP) were used as a negative control at the 
same concentration. In addition paclitaxel-loaded HSA nano-
particles (mpHSA) and free paclitaxel were tested for compar-
ison. Previously, we have developed acoustically and biologically 
compatible chambers for ultrasound-mediated delivery of thera-
peutic compounds to cancer cells. [ 24 ] A schematic of the set-up 
is illustrated in  Figure  4 a. Samples were added to the media 
of Michigan Cancer Foundation (MCF) 7 cells shortly before 
loading the chamber into the ultrasound set-up. As shown in 
Figure  4 b, there was no signifi cant effect of free paclitaxel with 
ultrasound. On the other hand, paclitaxel in nanocarriers with 
ultrasound effectively inhibited the growth of cancer cells in a 
synergistic manner. With ultrasound exposure, mpHSA-PFP 
exhibited a reduction in cell viability of 45.7% ± 4.62% after 24 h 
of incubation, whereas mpHSA decreased the cell viability to 
a smaller extent (14.5% ± 3.54%) at an equivalent concentra-
tion of paclitaxel (80 × 10 −9  M ). Acoustic droplet vaporization 
has been shown previously to induce cell membrane per-
meabilization. [ 25 ] In addition, rapidly expanding bubbles may 
increase contact between cell membranes and drugs, resulting 
in increased uptake of paclitaxel. Furthermore, mHSA-PFP 
also showed a small degree of cytotoxicity to the cancer cells 
in the ultrasound fi eld. Oscillating bubbles and or the fl uid 
motion induced by the process (microstreaming) could stretch 
and tear the membranes of nearby cells. [ 26,27 ] This mechanical 
force would initiate the cell swelling, cytolysis, and eventually 
death. [ 26 ] 
 During ultrasound exposure, the phase transition was moni-
tored using passive acoustic mapping (PAM) (Figure  4 c–h). [ 28 ] 
The evolution of cavitation activity was measured over time 
expressed as the maximum cavitation power from each frame of 
PAM data and the averaged spectra for the emissions from the 
focal point were also calculated in each experiment after recon-
struction. As shown in Figure  4 c, the annotated B-mode image 
as seen by the monitoring probe shows the sample holder 
when the focus of the HIFU transducer is in the centre of the 
image. In the absence of particles or nanodroplets the energy 
distribution was approximately uniform (max. value 91.86 
energy units) and represents the baseline signal level for the 
system due to background cavitation of the media, refl ections 
from the magnet, and electrical noise. As a result the time trace 
and spectra within the frequency range of the probe were both 
approximately fl at (Figure  4 g,h, blue lines). When the cells were 
treated with mpHSA nanoparticles not containing PFP, a small 
increase in the PAM signal was observed. Consequently, the 
map was no longer uniform, with a small peak visible toward 
the location of the HIFU focus (max. value 100.06 energy 
units) (Figure  4 e). The corresponding time trace (Figure  4 g, 
green line) showed that this was primarily due to increased 
cavitation in the fi rst frame of ultrasound data. Finally, with 
mpHSA-PFP nanodroplets a more pronounced increase in cavi-
tation energy was observed (max. value 140.68 energy units), 
which was maintained above baseline for the duration of the 
monitoring period (Figure  4 g, red line). The corresponding 
spectra (Figure  4 h, red line) showed the pronounced harmonic 
and ultraharmonic peaks suggestive of noninertial cavitation, 
as well as an increase in the broadband signal level associated 
with inertial cavitation. [ 29 ] These results imply that these ultra-
sound conditions were suffi cient to trigger vaporization of the 
nanodroplets into bubbles whose acoustic response was suffi -
cient for them to be observed using PAM. 
 To determine the main effects on the cancer cells, their size 
and shape were observed using an optical microscope, and pro-
pidium iodide (PI) was used to stain the nuclear DNA contents 
of each group ( Figure  5 ). During apoptosis, active biochemical 
events occur in the cells and consequentially induce morpho-
logical changes in the cell and DNA cleavage. [ 30 ] The optical 
images showed changes in cell morphology after treatment 
with the drug/droplets and ultrasound exposure, especially with 
mpHSA-PFP. The cell population was clearly reduced as shown 
in the images, also the morphology was changed on account of 
paclitaxel-induced apoptosis. Cell shrinkage and blebbing, typ-
ical of cell apoptosis, [ 31 ] were observed with mpHSA-PFP. Sim-
ilar cell shrinkage was observed with mpHSA nanoparticles. 
Interestingly, with mHSA-PFP, blebby cells with debris were 
occasionally observed perhaps because microbubbles created 
from nanodroplets damaged cells. Cells undergoing apoptosis 
could be identifi ed as a population with diminished DNA con-
tent shown as an accumulated sub G1 population. Cells treated 
with both mHSA-PFP and mpHSA showed a relatively high 
percentage of sub G1 population of 11.6% and 11%, respec-
tively, compared to cells only. The MCF-7 cells treated with 
mpHSA-PFP showed 26.4% of sub G1 cell fraction while 6.31% 
of cells was presented in the same phase in the free paclitaxel 
sample. The mpHSA-PFP enhanced not only the extent but also 
the rate of apoptosis-inducing cell death. Paclitaxel has antimi-
totic activity by preventing polymerization of tubulin polymers 
during replication in the late G2/M phase of the cell cycle, and 
the arrest in G2/M phase leads to cell death through an apop-
totic mechanism. [ 32 ] The cells with mpHSA showed relatively 
high cell population at this stage due to the paclitaxel working 
mechanism. Compared to mpHSA, mpHSA-PFP exhibited a 
lower percentage of cells at the G2/M stage because cells had 
already undergone the process of cell death. This is likely due 
to the synergistic effect of chemotherapy (paclitaxel) and phys-
ical effect of PFP vaporization. 
 In summary, we have developed a novel protein–polymer 
coated nanodroplet as an ultrasound-triggered imaging and 
therapeutic agent. This type of nanodroplet was demonstrated 
to be stable at body temperature over 10 d and highly responsive 
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 Figure 4.  a) Schematic illustration of instrumental setup for ultrasound-mediated intracellular delivery of paclitaxel. b) The viability of cells incubated 
for 24 h following treatment with ultrasound and: medium, mpHSA-PFP, mHSA-PFP, mpHSA or free paclitaxel, at an equivalent drug concentration 
of 1 µg mL −1 . c) Annotated B-mode image showing the sample chamber, magnet, and lid as seen from the imaging array. Axes are defi ned relative to 
the centre of the front face of the imaging array. d–f) Pre-exposure B-mode images with PAM overlay showing sum of all frames for each exposure for 
paclitaxel only (d), paclitaxel + nanoparticles (e), and paclitaxel + nanodroplets (f). Colour bars represent total cavitation energy (AU). g,h) Evolution 
of cavitation activity over time and spectra for the fi rst exposure from each sample. g) Maximum cavitation power (AU) from each frame of PAM data. 
g) Fast Fourier transform (FFT) magnitude (AU) of the reconstructed PAM signal from the focal point.
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to ultrasound stimulus. These protein–polymer nanodroplets 
showed excellent stability at in vivo temperatures and over pro-
longed time periods, as compared with single-chain surfactant 
coated nanodroplets. The nanodroplet formulation also con-
tains IONCs that make the droplets both magnetically respon-
sive and greatly improve droplet:bubble conversion effi ciency 
upon ultrasound exposure. Finally, we have demonstrated the 
effi cacy of the nanodroplets for the delivery of paclitaxel to 
cancer cells in an in vitro model. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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